DDInter864 DDInter1658
Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-controlled, hydrogel polymer reservoirs containing histrelin acetate that need to be replaced every 52 weeks.[L41700,L41715,L41755] Initially, histrelin implants were developed to reduce testosterone to castration levels in patients with advanced prostate cancer. The Vantas product was approved by the FDA in October 2004 for the palliative treatment of this condition. Vantas was later discontinued by Endo Pharmaceuticals Inc. on September 21, 2021. GnRH agonists are the first line of treatment for children with central precocious puberty (CPP) due to their capacity to reduce LH levels and the concentration of
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Histrelin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Histrelin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Risperidone
Histrelin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium citrate
Histrelin {u} may lead to a major life threatening interaction when taken with {v} Arsenic trioxide
Histrelin {u} may lead to a major life threatening interaction when taken with {v} Lefamulin
Histrelin may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Risperidone
Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Histrelin may lead to a major life threatening interaction when taken with Arsenic trioxide
Histrelin may lead to a major life threatening interaction when taken with Lefamulin